Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide in Chemotherapy-Naïve Symptomatic mCRPC
NCT01663415Phase 2Withdrawn
- Sponsor
- Astellas Pharma
- Start
- Aug 2012
- Primary completion
- Oct 2014
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Astellas Pharma. Primary endpoint: Radiographic Progression-Free Survival at 26 months. Planned start Aug 2012; status: withdrawn.
02
Drugs
enzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01663415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01663415.